GSK Sole Source Justification Under Federal Supply Schedule.pdf_signed_Redacted SAM.gov_Redacted.pdf

This is a Sole Source Justification under the Federal Supply Schedule submitted by the U.S. Department of State's Global Acquisitions office.

The Department of State, through the Office of Global Operations, is seeking approval to issue a sole-source delivery order under the Department of Veterans Affairs' Glaxosmith Kline federal supply schedule (contract number 36F79722D0178) for Fluarix and Flulaval Influenza vaccines for the 2026-2027 flu season. The estimated order value is $686,968.00. The vaccines are required to immunize embassy personnel and pediatric family members at over 200 embassies and consulates as disease prevention against four influenza virus strains. The supplies include Fluarix flu vaccines in prefilled syringes (10 per box) and Flulaval flu vaccines in prefilled syringes (10 per box). Cold chain storage will be maintained at an approved government receiving point, with the Office of Global Operations coordinating timely distribution to embassies and consulates before the start of the 2026-2027 flu season.

The justification cites FAR 8.405-6(a)(1)(i)(B), establishing that only one source—Glaxosmith Kline—is capable of providing these supplies at the required quality level because these vaccines are unique and highly specialized. Glaxosmith Kline is identified as the sole manufacturer of both Fluarix and Flulaval pediatric and adult influenza vaccines, which are the first Trivalent pediatric and adult flu vaccines approved by the FDA. The contracting officer has determined the anticipated contract action represents best value under FAR 8.405 and will evaluate the resultant price for reasonableness before award. The acquisition is structured as a Firm-Fixed-Price delivery order with no planned competitive solicitation.